Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial. The M/3331/0013B Study Group.
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 300) with that of AZT (n = 297) against human immunodeficiency virus type 1 in a randomized, double-blind, placebo-controlled trial. DLV exerted a transient antiviral effect, and mutations for resistance to DLV were found in more than 90% of subjects at week 12. The K103N mutation, which confers nonnucleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.
Joly
V
V
Department of Internal Medicine, Hôpital Bichat, Paris, France. veronique.joly@bch.ap-hop-paris.fr
Moroni
M
M
Concia
E
E
Lazzarin
A
A
Hirschel
B
B
Jost
J
J
Chiodo
F
F
Bentwich
Z
Z
Love
W C
WC
Hawkins
D A
DA
Wilkins
E G
EG
Gatell
A J
AJ
Vetter
N
N
Greenwald
C
C
Freimuth
W W
WW
de Cian
W
W
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D020008:Delavirdine / Q000627:therapeutic use*; D004311:Double-Blind Method; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D054303:HIV Reverse Transcriptase / Q000235:genetics; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics; D006801:Humans; D016896:Treatment Outcome; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D015215:Zidovudine; D020008:Delavirdine; D054303:HIV Reverse Transcriptase